We also examined S100A8/A9 as a potential therapeutic target in the treatment of colorectal carcinoma by analyzing the relationship between S100A8/A9, secreted by immune cells infiltrating the tumor along its invasive margin, and various clinicopathological parameters including tumor progression and metastasis. Here, S100A8 is linked to neoplasm.